Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.58 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.58 |
| ▸ | PPARA | Q07869 | 3/20 | 0.53 |
| ▸ | CTSS | P25774 | 4/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30428666 | 0.91 | SYK (0.53) | KLK7KLK5PPARACTSSSYK | |
| SCHEMBL344669 | 0.88 | PPARA (0.63) | KLK7KLK5PPARACTSSSYK | |
| SCHEMBL12585497 | 0.88 | KLK5 (0.65) | KLK7KLK5PPARACTSSSYK | |
| SCHEMBL10585294 | 0.88 | KLK5 (0.65) | KLK7KLK5PPARACTSSSYK | |
| SCHEMBL9943561 | 0.88 | KLK5 (0.65) | KLK7KLK5PPARACTSSSYK | |
| SCHEMBL4370045 | 0.88 | KLK5 (0.65) | KLK7KLK5PPARACTSSSYK | |
| SCHEMBL84710 | 0.88 | PPARA (0.63) | KLK7KLK5PPARACTSSSYK | |
| SCHEMBL9943562 | 0.88 | KLK5 (0.65) | KLK7KLK5PPARACTSSSYK | |
| SCHEMBL344670 | 0.88 | PPARA (0.63) | KLK7KLK5PPARACTSSSYK | |
| SCHEMBL14300984 | 0.87 | KLK5 (0.64) | KLK7KLK5PPARACTSSSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280935-B1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-10-15 | — | — | EP | disclosed |
| EP-2268606-B1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-8673946-B2 | 4-trimethylammonio-butyrates as CPT2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130030033-A1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8349893-B2 | 4-trimethylammonio-butyrates as CPT2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8344027-B2 | 4-dimethylaminobutyric acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120289554-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | ANDJELKOVIC MIRJANA (CH) | 2012-11-15 | — | — | US | disclosed |
| US-20090270505-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270500-A1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270505-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | CPT1B, CPT1A, CPT2 | KLK7 4860/4885KLK5 4783/4885PPARA 103/4885 |
| US-20090270500-A1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | CPT1A, CPT1B, CPT2 | KLK7 4705/4885KLK5 4490/4885PPARA 138/4885 |
| US-20120289554-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | CPT1B, CPT1A, CPT2 | KLK7 4860/4885KLK5 4783/4885PPARA 103/4885 |
| US-20130030033-A1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | CPT1A, CPT1B, CPT2 | KLK7 4705/4885KLK5 4490/4885PPARA 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.